Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.

Hsiao FC, Tung YC, Chou SH, Wu LS, Lin CP, Wang CL, Lin YS, Chang CJ, Chu PH.

Medicine (Baltimore). 2015 Dec;94(51):e2355. doi: 10.1097/MD.0000000000002355.

2.

Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.

Reed SD, Neilson MP, Gardner M, Li Y, Briggs AH, Polsky DE, Graham FL, Bowers MT, Paul SC, Granger BB, Schulman KA, Whellan DJ, Riegel B, Levy WC.

Am Heart J. 2015 Nov;170(5):951-60. doi: 10.1016/j.ahj.2015.08.015. Epub 2015 Aug 20.

PMID:
26542504
3.

Association between higher rates of cardioprotective drug use and survival in patients on dialysis.

Tang Y, Brooks JM, Wetmore JB, Shireman TI.

Res Social Adm Pharm. 2015 Nov-Dec;11(6):824-43. doi: 10.1016/j.sapharm.2014.12.007. Epub 2014 Dec 31.

PMID:
25657171
4.

Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study.

Dokainish H, Jewett L, Nieuwlaat R, Coulson J, Demers C, Lonn E, Healey J, Haynes B, Connolly S.

Open Cardiovasc Med J. 2014 Sep 30;8:94-101. doi: 10.2174/1874192401408010094. eCollection 2014.

5.

Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction.

Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM.

Circ Heart Fail. 2012 Nov;5(6):720-6. doi: 10.1161/CIRCHEARTFAILURE.111.966366. Epub 2012 Aug 30.

6.

Therapeutic ranges of serum digoxin concentrations in patients with heart failure.

Goldberger ZD, Goldberger AL.

Am J Cardiol. 2012 Jun 15;109(12):1818-21. doi: 10.1016/j.amjcard.2012.02.028. Epub 2012 Apr 11. No abstract available.

7.

A Study of Prescribing Valsartan in Out-patient Clinics at the Royal Hospital, Muscat, Oman.

Al-Salmi Z, Al-Raisi F, Al-Harbi A, Al-Rawahi A, Al-Naamani H.

Oman Med J. 2009 Jan;24(1):17-21. doi: 10.5001/omj.2009.5.

8.

β-Adrenergic receptor subtype signaling in heart: from bench to bedside.

Woo AY, Xiao RP.

Acta Pharmacol Sin. 2012 Mar;33(3):335-41. doi: 10.1038/aps.2011.201. Epub 2012 Jan 30. Review.

9.

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

Farsang C.

Vasc Health Risk Manag. 2011;7:605-22. doi: 10.2147/VHRM.S23468. Epub 2011 Sep 26. Review.

10.

Heart failure.

McKelvie RS.

BMJ Clin Evid. 2011 Aug 30;2011. pii: 0204. Review.

11.

Heart failure.

McKelvie RS.

BMJ Clin Evid. 2010 Feb 25;2010. pii: 0204. Review.

12.

The causes, consequences, and treatment of left or right heart failure.

Pazos-López P, Peteiro-Vázquez J, Carcía-Campos A, García-Bueno L, de Torres JP, Castro-Beiras A.

Vasc Health Risk Manag. 2011;7:237-54. doi: 10.2147/VHRM.S10669. Epub 2011 Apr 4. Review.

13.

The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis.

McAlister FA, Zhang J, Tonelli M, Klarenbach S, Manns BJ, Hemmelgarn BR; Alberta Kidney Disease Network.

CMAJ. 2011 Apr 5;183(6):655-62. doi: 10.1503/cmaj.101333. Epub 2011 Mar 21.

14.

The potential economic impact of restricted access to angiotensin-receptor blockers.

Guertin JR, Jackevicius CA, Cox JL, Humphries K, Pilote L, So DY, Tu JV, Wijeysundera H, Rinfret S; Canadian Cardiovascular Outcomes Research Team.

CMAJ. 2011 Feb 22;183(3):E180-6. doi: 10.1503/cmaj.100787. Epub 2011 Jan 24.

15.

Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.

Ma TK, Kam KK, Yan BP, Lam YY.

Br J Pharmacol. 2010 Jul;160(6):1273-92. doi: 10.1111/j.1476-5381.2010.00750.x. Review.

16.

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.

Kuenzli A, Bucher HC, Anand I, Arutiunov G, Kum LC, McKelvie R, Afzal R, White M, Nordmann AJ.

PLoS One. 2010 Apr 1;5(4):e9946. doi: 10.1371/journal.pone.0009946.

17.

Chronic heart failure: contemporary diagnosis and management.

Ramani GV, Uber PA, Mehra MR.

Mayo Clin Proc. 2010 Feb;85(2):180-95. doi: 10.4065/mcp.2009.0494. Review.

18.

The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Khan NA, Hemmelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM, Touyz RM, Padwal R, Leiter LA, Mahon JL, Hill MD, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Arnold MO, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, dechamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Katzmarzyk P, Tobe S, Lewanczuk RZ; Canadian Hypertension Education Program.

Can J Cardiol. 2008 Jun;24(6):465-75. Review.

19.
20.

Valsartan in the treatment of heart attack survivors.

Jugdutt BI.

Vasc Health Risk Manag. 2006;2(2):125-38. Review.

Items per page

Supplemental Content

Write to the Help Desk